Mario Contreraz named administrator of IU cancer center clinical trials office

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Mario Contreraz was named administrator of the Indiana University Melvin and Bren Simon Cancer Center’s Clinical Trials Office.

As administrator, Contreraz will provide overall direction for the strategy and vision for the Clinical Trials Office to ensure all NCI criteria and guidelines are met. He will also serve as a liaison between the administrative staff and the sponsors, collaborators, and regulatory agencies.

Contreraz had served as interim administrator for the Clinical Trials Office during the recruitment process. He initially joined the Clinical Trials Office in May 2016 as the research nurse administrator.

Prior to joining the CTO, Contreraz was a clinical research manager at the IU School of Medicine’s clinical research center, a clinical research nurse at the Krannert Institute of Cardiology, a nursing associate at Eli Lilly and Company, and an ER nurse at Eskenazi Health. He holds both a master’s of nurse administration, a master’s of business administration from Anderson University, and a bachelor’s degree in nursing from Ball State University.

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login